Chemomab Therapeutics Ltd (CMMB) Return on Assets ROA from the fourth quarter of 2025 to fourth quarter of 2024 and for the year 2025, Average High and Low, Fundamental Ratios from Dec 31 2025 to Dec 31 2024 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Chemomab Therapeutics Ltd   (NASDAQ: CMMB)


Chemomab Therapeutics Ltd 's ROA from the fourth quarter of 2025 to the fourth quarter of 2024 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Chemomab Therapeutics Ltd 's ROA in the fourth quarter of 2025?
Chemomab Therapeutics Ltd achieved a return on average assets (ROA) of 64.45 % in its fourth quarter of 2025, this is above CMMB's average return on assets of -26.17%.
Chemomab Therapeutics Ltd assets over the 12 months ending in its fourth quarter of 2025 are valued at $14 million

ROA fell compared to the third quarter of 2025, despite the net income growth of % from the third quarter of 2025.

However, within the Healthcare sector 715 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the third quarter of 2025 from to 4747.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Dec 31 2025)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter		 (Dec 31 2024)
IV. Quarter
Y / Y Total Assets Change 2.61 % -17.17 % -22.7 % -17.17 % -74.28 %
Y / Y Net Income Change -35.5 % - - - -42.43 %
Net Income (TTM) in million 9 14 14 14 14
Return On Assets (TTM) 64.45 % 100.71 % 95.76 % 90.74 % 86.7 %
CMMB's Total Ranking # 4747 # # # # 5106
Total Assets (TTM) in million 17 14 11 14 17
Seq. Total Assets Change 24.66 % 25.78 % -20.5 % -17.69 % 0.63 %
Seq. Net Income Change - - - - -

CMMB's 5 Years Annual ROA >> Back to CMMB Management Effectiveness >> Compare CMMB ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 324
Sector # 716
Overall # 4705

Return On Assets Statistics
High Average Low
105.61 %
-26.17 %
-137.3 %
(Dec 31 2018)   (Dec 31 2019)





Financial Statements
Chemomab Therapeutics Ltd 's Assets $ 17 million CMMB's Balance sheet
Chemomab Therapeutics Ltd 's Income $ 9 million Quarterly CMMB's Income Statement
CMMB's Income by Division See CMMB's Income by Division



Annual Return On Assets (Dec 31 2025)
FY 2025		 (Dec 31 2024)
FY 2024		 (Dec 31 2023)
FY 2023		 (Dec 31 2022)
FY 2022		 (Dec 31 2021)
FY 2021
Y / Y Total Assets Change 2.61 % -74.28 % -22.26 % -16.25 % 451.48 %
Total Assets in million 17 17 65 84 100
Y / Y Net Income Change - - - - -
Net Income in million -9 -14 -24 -28 -12
Annual Return On Assets -52.24 % -83.1 % -37.13 % -32.95 % -12.45 %

CMMB's 5 Years Annual ROA >> Back to CMMB Management Effectiveness >> Compare CMMB ROA to its Competitors



More Return On Assets Ratios
CMMB's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
CMMB's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for CMMB's Competitors
Subscribers only: Roa for Chemomab Therapeutics Ltd 's Suppliers
Subscribers only: Return On Assets for CMMB's Customers

You may also want to know
CMMB's Roi CMMB's Inventory Turnover Ratio CMMB's Growth Rates CMMB's Dividend Comparisons
CMMB's Profitability Ratios CMMB's Asset Turnover Ratio CMMB's Dividend Growth
CMMB's Roe CMMB's Valuation Ratios CMMB's Financial Strength Ratios CMMB's Dividend Payout Ratio



Companies with similar Return On Assets at Dec 31 2025, within Healthcare Sector ROA
Omada Health Inc   166.71 %
Scisparc Ltd  164.84 %
Silexion Therapeutics Corp  144.68 %
Interpace Biosciences Inc   135.21 %
Elutia Inc   129.48 %
Rigel Pharmaceuticals Inc  128.91 %
Capforce Inc   127.99 %
Kyntra Bio Inc   122.33 %
Icecure Medical Ltd  108.42 %
Atara Biotherapeutics Inc   87.55 %
Traws Pharma inc   86.12 %
Sanuwave Health Inc   65.98 %
Exelixis Inc   61.66 %
Entera Bio Ltd   61.28 %
Biocryst Pharmaceuticals Inc   55.61 %
Check Cap Ltd  55.30 %
Advanced Biomed Inc.  53.63 %
Enlivex Therapeutics Ltd  53.10 %
Tg Therapeutics Inc   51.88 %
Aurinia Pharmaceuticals Inc   50.24 %
Pulmatrix Inc   48.84 %
Earth Science Tech Inc   45.81 %
Q32 Bio Inc   45.06 %
Coherus Oncology inc   42.39 %
Elite Pharmaceuticals Inc   41.21 %
Alpha Tau Medical Ltd  40.35 %
Galmed Pharmaceuticals Ltd   37.04 %
Dariohealth Corp   36.94 %
Abeona Therapeutics Inc   35.76 %
Novavax inc   35.32 %

Date modified: 2026-07-07T10:09:58+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.